Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis

9 Dec 2009

Abstract excerpt

Cisplatin is one of the most widely used anticancer agents, displaying activity against a wide variety of tumors. However, development of drug resistance presents a challenging barrier to successful cancer treatment by cisplatin. To understand the mechanism of cisplatin resistance, we investigated the role of damaged DNA binding protein complex subunit 2 (DDB2) in cisplatin-induced cytotoxicity and apoptosis. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to DNA Repair Mechanisms
Share to Metal complexes synthesis and properties

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20013802
DOI: 10.1002/ijc.25112

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosisPMID 20013802Read ↗

Long noncoding RNA CEBPA-DT promotes cisplatin chemo-resistance through CEBPA/BCL2 mediated apoptosis in oral squamous cellular cancerSemantic proximity Read ↗

Increased ABCC2 expression predicts cisplatin resistance in non‐small cell lung cancerSemantic proximity Read ↗

Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1Semantic proximity Read ↗

DDB2 Suppresses Tumorigenicity by Limiting the Cancer Stem Cell Population in Ovarian CancerSemantic proximity Read ↗

Molecular mechanisms of cisplatin resistance in ovarian cancerSemantic proximity Read ↗

Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell linesSemantic proximity Read ↗

Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.Semantic proximity Read ↗

MEOX2 mediates cisplatin resistance in ovarian cancer via E2F target and DNA repair pathwaysSemantic proximity Read ↗

Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells.Semantic proximity Read ↗

Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1Semantic proximity Read ↗

Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancerSemantic proximity Read ↗

Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing RadiationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.